Effects of Yogurt With Probiotics in Adults With Type 2 Diabetes Mellitus
A 12-weeks Double Blind Trial of Effects of Yogurt With Probiotics in Adults With Type 2 Diabetes Mellitus
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Cordoba, Spain, 14004
- Instituto Maimónides de Investigación Biomédica de Córdoba
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with T2DM diagnosed at least one year ago.
- That they are outpatients.
- Between 25 and 65 years old.
Exclusion Criteria:
- Smoking patients.
- Lactose intolerance.
- Pregnancy or breastfeeding.
- Presence of kidney, liver, immunodeficiency, inflammatory bowel disease or thyroid disorder.
- Use of insulin, estrogen, progesterone or diuretic injections.
- Consumption of probiotic supplements two months before the start of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Premium probiotic yogurt
Participants receive 300 g/d of yogurt with concentrated and freeze-dried probiotic cultures for 12 weeks.
Also, the nutritional recommendations of the American Diabetes Association (ADA).
|
Cultures containing 3.7 × 10 ^ 9 CFU/mg
|
|
EXPERIMENTAL: Conventional yogurt
Participants receive 300 g/d of conventional yogurt for 12 weeks.
Also, the nutritional recommendations of the American Diabetes Association (ADA).
|
Cultures containing 3.7 × 10 ^ 6 CFU/mg
|
|
EXPERIMENTAL: no fermented dairy
Participants followed the American Diabetes Association (ADA) recommendations without including fermented dairy.
|
No probiotic cultures
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes from baseline in parameters associated with glucose homeostasis
Time Frame: Baseline and week 12
|
At time 0 and after 12 weeks of intervention and follow-up, it was determined in mg/dL following the protocols established for: HDL-c (high-density lipoprotein cholesterol), LDL-c (low-density lipoprotein cholesterol), triglycerides and glucose.
Likewise, glycosylated hemoglobin (HbA1c in percentage) was determined.
|
Baseline and week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in inflammatory parameters
Time Frame: Baseline and week 12
|
At time 0 and after 12 weeks of intervention and follow-up, the high sensitivity C-reactive protein (hs-CRP) was determined in plasma in mg/dL.
Likewise, interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-a) in ng/mL.
|
Baseline and week 12
|
|
Changes in oxidative stress parameters
Time Frame: Baseline and week 12
|
Superoxide dismutase, glutathione peroxidase and catalase (SOD, GPx, CAT, respectively) will be measured in U/mg by spectrophotometry at time 0 and after 12 weeks of intervention and follow-up.
|
Baseline and week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Pablo Perez Martinez, MD, Instituto Maimonides de Investigacion Biomedica de Cordoba, Spain
- Principal Investigator: Maria Ruiz Diaz Narvaez, DN, Faculty of Medical Science, Paraguay
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FMSParaguay
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.